DBV Technologies DBV.PA

DBV Technologies is headquartered in Montrouge, France and is a clinical-stage biopharmaceutical company responsible for developing Viaskin®, an investigational proprietary technology platform with potential applications in immunotherapy. The development of Viaskin® is based on epicutaneous immunotherapy, the company’s method for delivering biologically active compounds to the patient’s immune system through intact skin.

The company’s self-administered and non-invasive product candidates enable DBV Technologies to offer innovative solutions for food allergic patients. Current company programs include clinical trials and preclinical development of Viaskin Peanut, Viaskin Milk, Viaskin Egg, and other solutions.

In 2018, the company announced preliminary results from Part B of the Viaskin Milk study, reporting that a statistically significant desensitisation to milk was found in children ages two to 11 who were treated with Viaskin Milk for 12 months.

DBV Technologies operates in France and across the US. The company’s financial results for the first half of fiscal 2019 include operating income of €7.1 million. Track this instrument for more updates and news on the current DBV.PA value.